FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in ARANOTE trial.
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer Read More »
First systemic therapy to improve survival when used before/after surgery for MIBC patients ineligible for cisplatin chemotherapy.
GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint inhibitors in 994-patient analysis.
PSA nadir <0.2 ng/mL within 9 months shows 54% lower death risk vs 22% for ≥90% decline in mCSPC veterans receiving ADT-based therapy.
XBCM urinary biomarker reduces cystoscopies by 55% in high-grade NMIBC surveillance without compromising recurrence detection safety.
Researchers identified six plant-derived flavonoids toxic to bladder cancer cells using innovative Cell Painting microscopy technology.
Cell Painting Identifies Flavonoids That Are Toxic to Bladder Cancer Cells Read More »
Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal toxicity.
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy Read More »
FDA approves mitomycin (Zusduri) for recurrent low-grade NMIBC: 78% complete response, 79% maintain response ≥12 months in ENVISION trial.
68Ga-NY104 PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma.
68Ga-NY104 PET/CT Outperforms 18F-FDG PET/CT in Metastatic ccRCC Read More »
CR rates greater than 80% achieved with TAR-200 device – first time we’ve seen rates this high in BCG-unresponsive NMIBC patients.
